Relugolix (Orgovyx®)
Clinical Indication
For treating hormone sensitive prostate cancer
Date of classification
November 2024
Yellow
Specialist recommendation: Medicines initiated (and stabilised where appropriate) or recommended by a specialist service for prescribing in primary care. Requests should be clearly communicated either through written communication including using approved paperwork if available or verbal means as appropriate .